<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study was undertaken to show that a high survival rate can be obtained in B-cell (Burkitt and large B-cell) <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and L3 <z:hpo ids='HP_0001909'>leukemia</z:hpo> with multiagent chemotherapy adapted to the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden (stage, resection status, percentage of blasts in bone marrow, and central <z:mp ids='MP_0008912'>nervous</z:mp> system [<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>] involvement) and early response to chemotherapy, to investigate actual prognostic factors, and to see if large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> can be treated with the same regimen as Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients were classified into 3 risk groups </plain></SENT>
<SENT sid="2" pm="."><plain>Group A (resected stage I and abdominal stage II) received 2 courses of <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Group B (patients not eligible for groups A or C) received 5 courses of chemotherapy with, in addition, high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, 3 g/m(2) over 3 hours; infusional <z:chebi fb="0" ids="28680">cytarabine</z:chebi>; and intrathecal (IT) <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Group C (patients with <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> with at least 70% of blasts in bone marrow) received 8 courses with, in addition, high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, 8 g/m(2); high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi>; <z:chebi fb="0" ids="4911">etoposide</z:chebi>; and triple IT </plain></SENT>
<SENT sid="5" pm="."><plain>Except in group A, treatment started with a prephase (COP, low-dose <z:chebi fb="0" ids="28445">vincristine</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>) </plain></SENT>
<SENT sid="6" pm="."><plain>It was intensified for patients who did not respond to COP in group B and any patient with residual viable cells after the consolidation phase </plain></SENT>
<SENT sid="7" pm="."><plain>A total of 561 patients were enrolled in the SFOP LMB89 protocol (July 1989-June 1996) </plain></SENT>
<SENT sid="8" pm="."><plain>Five-year survival is 92.5% (95% confidence interval [CI], 90%-94%) and event-free survival (EFS) 91% (95% CI, 89%-93%) </plain></SENT>
<SENT sid="9" pm="."><plain>EFS is 98% (95% CI, 90%-100%), 92% (95% CI, 89%-95%), and 84% (95% CI, 77%-90%) for group A, B, and C, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>In group B, multivariate analysis of prognostic factors showed that a <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase level more than 2-fold the <z:mpath ids='MPATH_458'>normal</z:mpath> value, no response after COP, and age of at least 15 years were associated with a lower EFS </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement was the only prognostic factor in group C </plain></SENT>
<SENT sid="12" pm="."><plain>(Blood </plain></SENT>
<SENT sid="13" pm="."><plain>2001;97:3370-3379) </plain></SENT>
</text></document>